Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants
← catalyst calendarNCT07646548 · readout in 42 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
40estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-11 | actual | When the study began enrolling |
| Primary completion | 2026-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Biological: Dupilumab coformulated with berahyaluronidase alfa — also filed as SAR231893, Dupixent
- Biological: Dupilumab — also filed as SAR231893, Dupixent
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetic (PK) parameter in serum: Cmax of dupilumab
measured From Day 1 to Day 85 (end of study)
PK parameter in serum: AUClast of dupilumab
measured From Day 1 to Day 85 (end of study)
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed